Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q™), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women

被引:31
作者
Flood, Emuella M. [1 ]
Beusterien, Kathleen M.
Green, Hannah
Shikiar, Richard
Baran, Robert W.
Amonkar, Mayur M.
Cella, David
机构
[1] Oxford Outcomes Inc, Bethesda, MD USA
[2] United Biosource Corp, Ctr Hlth Outcomes Res, Bethesda, MD 20814 USA
[3] Roche Labs, Nutley, NJ USA
[4] GlaxoSmithKline, Collegeville, PA USA
[5] Evanston NW Healthcare, Ctr Outcomes Res & Educ, Evanston, IL USA
关键词
D O I
10.1186/1477-7525-4-42
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: The Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q) is a new measure of patient satisfaction with bisphosphonate treatment for osteoporosis. The objective of this study was to evaluate the psychometric characteristics of the OPSAT-Q. Methods: The OPSAT-Q contains 16 items in four subscales: Convenience, Confidence with Daily Activities, Side Effects, and Overall Satisfaction. All four subscale scores and an overall composite satisfaction score (CSS) can be computed. The OPSAT-Q, Osteoporosis Targeted Quality of Life (OPTQoL), and sociodemographic/clinical questionnaires, including 3 global items on convenience, functioning and side effects, were self-administered to women with osteoporosis or osteopenia recruited from four US clinics. Analyses included item and scale performance, internal consistency reliability, reproducibility, and construct validity. Reproducibility was measured using the intraclass correlation coefficient (ICC) via a follow-up questionnaire completed by participants 2 weeks post baseline. Results: 104 women with a mean age of 65.1 years participated. The majority were Caucasian (64.4%), living with someone (74%), and not currently employed (58.7%). 73% had osteoporosis and 27% had osteopenia. 80% were taking weekly bisphosphonates and 18% were taking daily medication (2% missing data). On a scale of 0 - 100, individual patient subscale scores ranged from 17 to 100 and CSS scores ranged from 44 to 100. All scores showed acceptable internal consistency reliability (Cronbach's alpha > 0.70) ( range 0.72 to 0.89). Reproducibility ranged from 0.62 ( Daily Activities) to 0.79 ( Side Effects) for the subscales; reproducibility for the CSS was 0.81. Significant correlations were found between the OPSAT-Q subscales and conceptually similar global measures ( p < 0.001). Conclusion: The findings from this study confirm the validity and reliability of the OPSAT-Q and support the proposed composition of four subscales and a composite score. They also support the use of the OPSAT-Q to examine the impact of bisphosphonate dosing frequency on patient satisfaction.
引用
收藏
页数:9
相关论文
共 18 条
[1]
[Anonymous], DESIGNING CLIN RES
[2]
Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease [J].
Atkinson M.J. ;
Sinha A. ;
Hass S.L. ;
Colman S.S. ;
Kumar R.N. ;
Brod M. ;
Rowland C.R. .
Health and Quality of Life Outcomes, 2 (1)
[3]
Development of the satisfaction with Inhaled Asthma Treatment Questionnaire [J].
Campbell, JL ;
Kiebert, GM ;
Partridge, MR .
EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (01) :127-134
[4]
The impact of compliance with osteoporosis therapy on fracture rates in actual practice [J].
Caro, JJ ;
Ishak, KJ ;
Huybrechts, KF ;
Raggio, G ;
Naujoks, C .
OSTEOPOROSIS INTERNATIONAL, 2004, 15 (12) :1003-1008
[5]
Reliability of an osteoporosis-targeted quality of life survey instrument for use in the community: OPTQoL [J].
Chandler, JM ;
Martin, AR ;
Girman, C ;
Ross, PD ;
Love-McClung, B ;
Lydick, E ;
Yawn, BP .
OSTEOPOROSIS INTERNATIONAL, 1998, 8 (02) :127-135
[6]
Development and validation of a disease-specific treatment satisfaction questionnaire for gastro-oesophageal reflux disease [J].
Coyne, KS ;
Wiklund, I ;
Schmier, J ;
Halling, K ;
Degl'Innocenti, A ;
Revicki, D .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (09) :907-915
[7]
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis [J].
Cramer, JA ;
Amonkar, MM ;
Hebborn, A ;
Altman, R .
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (09) :1453-1460
[8]
Biological properties and mechanism of action of ibandronate: Application to the treatment of osteoporosis [J].
Epstein, S ;
Zaidi, M .
BONE, 2005, 37 (04) :433-440
[9]
Development and validation of a discriminative quality of life questionnaire for osteoporosis (the OPTQoL) [J].
Lydick, E ;
Zimmerman, SI ;
Yawn, B ;
Love, B ;
Kleerekoper, M ;
Ross, P ;
Martin, A ;
Holmes, R .
JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (03) :456-463
[10]
A new treatment satisfaction measure for asthmatics: A validation study [J].
Mathias, SD ;
Warren, EH ;
Colwell, HH ;
Sung, JCY .
QUALITY OF LIFE RESEARCH, 2000, 9 (07) :873-882